Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
Trial ID or NCT#
This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric and adult subjects with treatment-resistant seizure disorders, including Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS). All participants have rolled over from previous trials: INS011-14-029 (NCT02324673), INS011-14-024 (NCT02318537), or INS011- 14-025 (NCT02318563).
Contact us to find out if this trial is right for you.
About this Clinical Trial
A Multicenter Open-label Plexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidol Oral Solution as an Adjunctive Treatment for Pediatric and Adult Subjects with a Treatment Resistant Seizure Disorder Who Complete INS011-14-029, INS011-01-025, or INS011-14-025
Your Message Will Go ToMaria Coburn
Go Back To The Trial